ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

April 6, 2018: By Jon Swedien

ThromboGenicsThromboGenics’ candidate for diabetic macular edema (DME) was safe and well tolerated in a Phase I/II study, the Belgium company announced April 4.

The candidate, THR-317 (anti-PlGF), is a recombinant humanized monoclonal antibody directed against the receptor-binding site of human placental growth factor (PlGF), ThromboGenics said.

In preclinical models, anti-PlGF has been shown to be anti-inflammatory, in addition to anti-angiogenic and anti-edema, the company said.

The study enrolled 49 patients and included anti-VEGF naïve patients as well as sub-optimal anti-VEGF responders, ThromboGenics said.

Thirty percent of the anti-VEGF treatment naïve study subjects treated with THR-317 in the 8 mg group showed a greater than 15-letter gain from baseline at day 90 compared with 5.3 percent in the 4 mg group, the company said.

ThromboGenics said the data support a next study evaluating THR-317 in combination with an anti- VEGF, and the company hopes to initiate a clinical trial in Q2-2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT